3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Colorectal Neoplasms
3
Turcot syndrome
2
Medulloblastoma
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Rhabdoid Tumor
1
Recurrence
1
Rectal Neoplasms
1
Pyloric Stenosis, Hypertrophic
1
Pinealoma
1
Peutz-Jeghers Syndrome
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Mouth Neoplasms
1
Locally Advanced Rectal Cancer
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Ependymoma
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Adenomatous Polyposis Coli
1
Interventions
Cyclophosphamide
21
venetoclax
18
pembrolizumab
16
Dexamethasone
16
fludarabine
14
Cytarabine
13
Gemcitabine
9
pomalidomide
8
Rituximab
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
Immunotherapy, Adoptive
7
selinexor
6
Paclitaxel
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Oxaliplatin
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
Celecoxib
×
Clear all
NCT01356290
2026-02-23
MEMMAT
Medical University of Vienna
Phase 2
Recruiting
232 enrolled